skip to content

Market News

PureTech notes Vedanta Biosciences' collaboration

11 August 2016 09:31

PureTech Health noted that Vedanta Biosciences has entered into a translational collaboration with the NYU Langone Medical Center focused on developing microbiome-derived immunotherapies for cancer patients being treated with checkpoint inhibitors.

The collaboration seeks to leverage Vedanta's portfolio of immune activating microbial cocktails for use in standalone immunotherapy and in combination with checkpoint inhibitors.

Daphne Zohar, Co-Founder and Chief Executive Officer at PureTech, said:

"Recent studies have highlighted the role of the microbiome in immuno-oncology, and it's exciting to work with Dr. Weber and the NYU Langone Medical Center to expand Vedanta's pipeline of immune-boosting microbiome derived therapeutics and checkpoint inhibitor combinations."

At 9:31am: (LON:PRTC) Puretech Health Plc share price was -2.25p at 158.75p

Story provided by

Related Company: PRTC

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?


Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.